Nemaura Medical (NMRD) is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) designed to help people with diabetes and pre-diabetics to better manage their glucose levels by spending more time in range. Insulin users can adjunctively use sugarBEAT® when calibrated with a finger-stick glucose reading. SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five-minute intervals for periods of up to 24 hours.
A live Q&A session, open to current and prospective investors, will immediately follow CEO Dr. Faz Chowdhury's presentation.
For more information on Nemaura Medical (NASDAQ: NMRD), visit http://www.nmrdinfo.com/